scholarly journals EGFR mutation is not a prognostic factor in completely resected lymph node–negative pulmonary adenocarcinoma (LNNPA)

2019 ◽  
Vol 30 ◽  
pp. v589
Author(s):  
N. Leeladejkul ◽  
P. Chantranuwat ◽  
P. Sitthideatphaiboon ◽  
C. Teerapakpinyo ◽  
S. Shuangshoti ◽  
...  
2016 ◽  
Vol 212 (4) ◽  
pp. 775-780 ◽  
Author(s):  
Bruno Märkl ◽  
Tina Schaller ◽  
Yuriy Kokot ◽  
Katharina Endhardt ◽  
Hallie Kretsinger ◽  
...  

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 4561-4561
Author(s):  
R. Shridhar ◽  
G. W. Dombi

4561 Purpose: To determine the prognostic significance of the lymph node ratio (ratio of number of positive lymph nodes to number of dissected lymph nodes) in gastric cancer patients. Methods: We retrospectively analyzed 10,176 gastric patients from 1990–2003 who underwent curative gastrectomy from the SEER database. Survival curves were calculated according to the Kaplan-Meier method and analyzed with log-rank test. Multivariate analysis of prognostic factors related to survival was performed by the Cox proportional hazard model. Results: The lymph node ratio (LNR) was a strong predictor of survival. LNR was equally predictive of survival whether the analysis was restricted to patients with <15 lymph nodes dissected or >15 lymph nodes dissected. Survival of patients with a LNR of 0.1–5% was not significantly different than node negative patients; however, survival of patients with a LNR of 5–10% was significantly different than node negative patients. Multivariate analysis showed that LNR, T-stage, tumor size, and number of lymph nodes positive were independent prognostic predictors of death and that LNR was the strongest predictor for death. Multivariate analysis showed that the number of lymph nodes dissected was an independent prognostic factor for survival. Moreover, LNR was an independent prognostic factor for N1 and N2 patients by AJCC staging. LNR trended toward significance in AJCC N3 patients. Conclusions: LNR was the strongest predictor of death in gastric cancer patients when compared to T-stage, number of lymph nodes positive, and tumor size. LNR is equally predictive regardless of the adequacy of the lymph node dissection. No significant financial relationships to disclose.


2006 ◽  
Vol 9 (1) ◽  
pp. 41 ◽  
Author(s):  
So-Youn Jung ◽  
Wonshik Han ◽  
Hyuk Jai Shin ◽  
Jeong Eon Lee ◽  
Ki-Tae Hwang ◽  
...  

1993 ◽  
Vol 29 (8) ◽  
pp. 1141-1145 ◽  
Author(s):  
A.M. Schor ◽  
M.E.H.M. Van Hoef ◽  
S.S. Dhesi ◽  
A. Howell ◽  
W.F. Knox

2019 ◽  
Vol 32 (11) ◽  
Author(s):  
J Oguma ◽  
S Ozawa ◽  
A Kazuno ◽  
M Yamamoto ◽  
Y Ninomiya ◽  
...  

SUMMARY The relationship between lymphovascular invasion (LVI) and prognosis in patients with superficial esophageal squamous cell carcinoma (SESCC) is unclear. The aim of this study is to evaluate prognostic factors in patients with lymph node-negative SESCC. A total of 195 patients with pathologically confirmed T1a-MM, T1b, and lymph node-negative SESCC were retrospectively reviewed in this study. Overall, the disease-free survival (DFS) rate was poorer in the lymphatic invasion-positive group than in the lymphatic invasion-negative group (p = 0.002) and a multivariate analysis suggested that lymphatic invasion was the only independent prognostic factor of DFS in patients with lymph node-negative SESCC (HR = 4.075, p = 0.005). Distant organ recurrence occurred in one patient (1/52, 1.9%) in the T1b-SM2 group and in six patients (6/61, 9.7%) in the T1b-SM3 group; all of these patients had LVI. LVI-positive patients had a poorer DFS than invasion-negative patients in the T1b-SM2 and SM3 groups (p = 0.026), and a multivariate analysis suggested that LVI was the only independent prognostic factor of DFS in patients with lymph node-negative SM2 and SM3 SESCC (HR = 5.165, p = 0.031). Lymph node-positive patients had a significantly poorer DFS rate than lymph node negative and LVI positive patients among the SM2 and SM3 SESCC patients (p = 0.018). The present results suggested that LVI was an independent prognostic factor in patients with SM2 and SM3 lymph node-negative SESCC; however their prognosis was not worse than that of patients with lymph node-positive SM2 and SM3 SESCC, for whom adjuvant therapy is indicated as a standard treatment.


PLoS ONE ◽  
2019 ◽  
Vol 14 (3) ◽  
pp. e0212527
Author(s):  
Nina Gran Egeland ◽  
Marie Austdal ◽  
Bianca van Diermen-Hidle ◽  
Emma Rewcastle ◽  
Einar G. Gudlaugsson ◽  
...  

2012 ◽  
Vol 13 (11) ◽  
pp. 5767-5772 ◽  
Author(s):  
Abbas Rezaianzadeh ◽  
Abdolrasoul Talei ◽  
Abdereza Rajaeefard ◽  
Jafar Hasanzadeh ◽  
Hamidreza Tabatabai ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document